Circio Holding ASA

Regulatory Filings • Oct 1, 2025

Circio to present comprehensive circVec-AAV in vivo data package at ESGCT 2025

Circio to present comprehensive circVec-AAV in vivo data package at ESGCT 2025

* Circio will present its circVec expression platform at the European Society

of Gene and Cell Therapy (ESGCT) annual meeting, taking place on 7-10

October 2025 in Seville, Spain

* In the presentation, Circio will summarize the most recent development of

circVec-AAV in vivo demonstrating significant advantages over conventional

AAVs in heart and other tissues

* ESGCT is one of the most prestigious and widely attended international

conferences in the gene and cell therapy field

Oslo, Norway 1 October 2025 -- Circio Holding ASA (OSE: CRNA), a biotechnology

company developing powerful circular RNA technology for next generation

nucleic acid medicine, today announces that the European Society of Cell and

Gene Therapy (ESGCT) has selected a Circio abstract for poster presentation at

its annual meeting 2025. The presentation will detail how Circio is enhancing

gene and cell therapy using circVec, its circular RNA vector expression

technology. Specifically, Circio will summarize recent in vivo results

demonstrating significant advantages of its circVec-AAV platform over

conventional AAVs in heart and other tissues.

"Circio s most recent in vivo results continue to demonstrate circVec s strong

potential as a novel expression system for enhanced gene and cell therapy. The

prestigious ESGCT annual meeting provides an excellent opportunity for us to

showcase our latest pre-clinical data to a wide industry and academic

audience," said Dr. Thomas B. Hansen, CTO of Circio. "At this year s

conference, we will present the major advances we have made to enhance

conventional AAV gene therapy using the circVec platform, showing

statistically significant increases in expression in multiple tissues for

several circVec-AAV variants."

Title of presentation:

CircVec: Enhancing gene and cell therapy using circular RNA vector expression

technology (poster no. 1041)

Presenter:

CTO Dr. Thomas B Hansen & CSO Dr. Victor Levitsky

Time:

14:00hrs CEST, 8 October 2025

Location:

Fibes, Seville, Spain

For further information, please contact:

Erik Digman Wiklund, CEO

Phone: +47 413 33 536

Email: erik.wiklund@circio.com

Neil Hunter -- Hunter PR

Phone: +44 782 125 5568

Email: neiljameshunter@gmail.com

About Circio

Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing powerful circular RNA

vector expression technology for next generation nucleic acid medicine.

Circio has established a unique circular RNA (circRNA) vector expression

technology for next generation RNA, DNA and viral therapeutics. The

proprietary circVec platform is based on a modular genetic construct designed

for efficient biogenesis of multifunctional circRNA inside target cells. The

circVec platform has applications in multiple therapeutic settings, including

genetic medicine, cell therapy and chronic disease. It has demonstrated

75-fold increased RNA half-life and up to 40-fold enhanced protein expression

vs. conventional mRNA-based viral and non-viral vector systems, with the

potential to become a new gold-standard gene expression technology. The

circVec R&D activities are being conducted by the wholly owned subsidiary

Circio AB in Stockholm, Sweden.